Trademark Overview
On Thursday, April 16, 2026, a trademark application was filed for NXERA with the United States Patent and Trademark Office. The USPTO has given the NXERA trademark a serial number of 99767902. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Thursday, April 16, 2026. This trademark is owned by Nxera Pharma Co., Ltd.. The NXERA trademark is filed in the Computer & Software Products & Electrical & Scientific Products, Advertising, Business and Retail Services, and Computer & Software Services & Scientific Services categories with the following description:
Software, application software, computer software, computer software platforms, artificial intelligence, generative artificial intelligence software, generative design software, deep learning software, neural networks software and machine learning software, large language models software, frontier models software, foundation models software, retrieval augmented generation trained models software, knowledge graphs software; computer software for accessing, browsing and searching online databases; computer software for searching, tracking, modelling, exploration and analysis of data; artificial intelligence software for searching, tracking, modelling, exploration and analysis of data; databases; computer databases; data banks; electronic databases; interactive databases; data processing software; all of the aforementioned being in the field of life sciences, chemical and biological drug discovery, molecular simulation, target identification, lead identification, pharmaceuticals, design a...
design and development of computer software; providing online non-downloadable computer software; providing online non-downloadable computer software for searching, tracking, modelling, exploration and analysis of data; computer programming; compilation of scientific information; preparation of scientific and technological reports; provision of scientific and technical information and data; information, advisory and consultancy services relating to all of the aforesaid services; Artificial intelligence as a service (AIaaS), software as a service, platform as a service (PaaS); all of the aforementioned being in the field of life sciences, chemical and biological drug discovery, molecular simulation, target identification, lead identification, pharmaceuticals, design and development of drugs, diagnostics and therapeutics.
Database management; computer database management; collection and compilation of data; compilation and systemisation of information and data in computer databases; compilation of information and data relating to life sciences, chemical and biological drug discovery, target identification, lead identification, pharmaceuticals, design and development of drugs, diagnostics and therapeutics; data processing, systemisation and management; data processing services; providing business statistical information for use in predictive analytics and predictive modelling via computer databases; information, advisory and consultancy services relating to all of the aforesaid services.
